Grant of awards under Long Term Incentive Plan

23 April 2026

AOTI, INC. (the "Company" or "Group" or "AOTI")

Grant of performance share awards to CEO, CFO and COO under Long Term Incentive Plan

AOTI, INC. (AIM: AOTI), a medical technology group focused on delivering outcomes-based care at home, by more durable healing of wounds and the prevention of amputations, announces that on 22 April 2026, the Company granted awards over ordinary shares in the form of options (Performance Awards) under the AOTI Long Term Incentive Plan (LTIP) to Mike Griffiths, CEO, Jayesh Pankhania, CFO, and Anthony Moffatt, COO, who are Persons Discharging Managerial Responsibilities (PDMR), as detailed below:

The Performance Awards will vest three years from the grant date conditional on meeting three-year performance conditions as described below.

50% of an award is subject to an Adjusted EBITDA¹ performance condition measured over a three-year period ending 31 December 2028.

50% of an award is subject to an Adjusted EBITDA margin² performance condition measured over a three-year period ending 31 December 2028.

¹ Adjusted EBITDA is an unaudited non-GAAP measure: Earnings before interest, taxation, depreciation, amortisation and non-underlying items.

² Adjusted EBITDA margin is Adjusted EBITDA divided by Revenue

END

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO₂^®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO₂^® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO₂^® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO₂^® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net